Intensive treatment for preschoolers with autism using pivotal response training

A Center Based Randomized Controlled Trial of Pivotal Response Treatment for Preschoolers with Autism

Not applicable Interventional Stanford University · NCT03778827

This study tests whether a special training program for parents and preschoolers with autism can improve social communication skills better than waiting for treatment.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment44 (estimated)
Ages2 Years to 3 Years
SexAll
SponsorStanford University Academic / other
Locations1 site (Stanford, California)
Trial IDNCT03778827 on ClinicalTrials.gov

What this trial studies

This study examines the effectiveness of pivotal response training (PRT) in a center-based preschool environment to address social communication deficits in children with autism spectrum disorder (ASD). It compares the outcomes of children receiving PRT combined with parent training to those in a delayed treatment group. The study will involve 44 children aged 2 to 3.11 years diagnosed with ASD, utilizing established diagnostic tools to confirm eligibility. The intervention aims to provide a naturalistic behavioral approach based on applied behavior analysis principles.

Who should consider this trial

Good fit: Ideal candidates are children aged 2 to 3.11 years diagnosed with autism spectrum disorder and exhibiting social communication deficits.

Not a fit: Patients who are not within the specified age range or do not have a diagnosis of autism spectrum disorder may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve social communication skills in young children with autism.

How similar studies have performed: Previous studies have shown promising results for pivotal response training in improving outcomes for children with autism, indicating a potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of Autism Spectrum Disorder (ASD) based on clinical interview and Diagnostic and Statistical Manual, 5th edition (DSM-5) and confirmed using the Autism Diagnostic Interview Revised (ADI-R) and Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2) or Childhood Autism Rating Scale (CARS-2); Diagnostic and Statistical Manual, 5th edition (DSM-5), and expert clinical opinion
* Boys and girls between 2 years and 3 years and 11 months
* Ability to participate in the testing procedures to the extent that valid standard scores can be obtained
* Stable treatment (e.g., applied behavior analysis (ABA), speech therapy, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation
* Developmentally delayed with Mullen Scales of Early Learning (MSEL) or Developmental Profile (DP-4) composite score below 85 (1 Standard Deviation below the mean)
* Availability of at least one English-speaking parent who can consistently participate in parent training and research measures.

Exclusion Criteria:

* Current or lifetime diagnosis of severe psychiatric disorder (e.g., bipolar disorder, etc.)
* Presence of active medical problem (e.g., unstable seizure disorder or heart disease)
* Child primary language other than English
* Previous adequate trial of Pivotal Response Treatment
* More than 15 hours per week of in-home applied behavior analysis (ABA).

Where this trial is running

Stanford, California

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Autism Spectrum DisorderAutismPivotal Response Treatment
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.